Skip to main content
The FDA has approved an ethyl ester of eicosapentaenoic acid (EPA) to treat hypertriglyceridemia. It is the second drug in this class after Lovaza, which contains esters of both EPA and DHA (docosahexaenoic acid). Icosapent ethyl is marketed by Amarin Pharmaceuticals, a Dublin, Ireland-based company, as Vascepa.

Pharmacology Update: Icosapent Ethyl Capsules (Vascepa™)